Skip to main content

Amoxicillin (Monograph)

Brand names: Amoxil, Larotid
Drug class: Aminopenicillins

Medically reviewed by Drugs.com on Apr 10, 2024. Written by ASHP.

Introduction

Antibacterial; β-lactam antibiotic; aminopenicillin.6 62

Uses for Amoxicillin

Otitis Media

Treatment of acute otitis media (AOM).1 140 176 177 190 192 199 200 209 210 211 683 AAP, AAFP, CDC, and others consider amoxicillin the drug of first choice for initial treatment of AOM, unless the infection is suspected of being caused by β-lactamase-producing bacteria resistant to the drug, in which case the fixed combination of amoxicillin and clavulanate is recommended for initial treatment.190 200 202 204 205 210 683 Those who fail to respond to amoxicillin should be retreated with amoxicillin and clavulanate.683

Has been used for management of otitis media with effusion† [off-label] (OME).193 206 208 219 221 227 Anti-infectives not usually recommended;111 115 206 208 219 221 245 they provide only limited benefit in enhancing resolution of effusion and may promote resistance.115 207 208 219 AAP, AAFP, and others recommend watchful waiting for 3 months from date of effusion onset or diagnosis in those 2 months to 12 years of age who are not at risk for speech, language, or learning problems; some suggest a short course of anti-infectives may be considered for possible short-term benefits when parent and/or caregiver expresses a strong aversion to impending surgery.245 If anti-infectives are used, amoxicillin or the fixed combination of amoxicillin and clavulanate recommended.219 221 227

Pharyngitis and Tonsillitis

Treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β-hemolytic streptococci; GAS) and prevention of initial attacks (primary prevention) of rheumatic fever.1 6 35 39 108 109 110 292 375 580

AAP, IDSA, and AHA recommend a penicillin regimen (i.e., 10 days of oral penicillin V or oral amoxicillin or single dose of IM penicillin G benzathine) as treatment of choice for S. pyogenes pharyngitis and tonsillitis;292 375 580 other anti-infectives (narrow-spectrum oral cephalosporins, oral macrolides, oral clindamycin) recommended as alternatives in penicillin-allergic patients.292 375 580

If signs and symptoms of pharyngitis recur shortly after initial treatment and presence of S. pyogenes documented, retreatment with original or alternative anti-infective recommended.292 375 580 Alternative regimens recommended for retreatment include a narrow-spectrum oral cephalosporin, oral clindamycin, oral fixed combination of amoxicillin and clavulanate, oral macrolide, or IM penicillin G benzathine.292 375 580

Consider that multiple, recurrent episodes of symptomatic pharyngitis within a period of several months to years may indicate that patient is a long-term pharyngeal carrier of S. pyogenes experiencing repeated episodes of nonstreptococcal (e.g., viral) pharyngitis.292 375 580

Treatment not usually recommended for asymptomatic chronic pharyngeal carriers of S. pyogenes.292 375 580 Eradication of the carrier state may be desirable in certain situations (e.g., community outbreak of acute rheumatic fever, acute poststreptococcal glomerulonephritis, or invasive S. pyogenes infections; outbreak of S. pyogenes pharyngitis in a closed or partially closed community; multiple episodes of documented symptomatic S. pyogenes pharyngitis occurring within a family for many weeks despite appropriate treatment; personal or family history of acute rheumatic fever).292 580 In such situations, recommended regimens include oral clindamycin, oral fixed combination of amoxicillin and clavulanate, or either IM penicillin G benzathine or oral penicillin V used in conjunction with oral rifampin.292 580

Respiratory Tract Infections

Treatment of lower respiratory tract infections caused by susceptible Streptococcus (α- or β-hemolytic strains only), S. pneumoniae, Staphylococcus, or H. influenzae.1 6 57 62 73 81

Skin and Skin Structure Infections

Treatment of skin and skin structure infections caused by susceptible Streptococcus (α- or β-hemolytic strains only), Staphylococcus, or Escherichia coli.1

Urinary Tract Infections (UTIs)

Treatment of UTIs caused by susceptible Enterococcus faecalis, Escherichia coli, or Proteus mirabilis.1 3 4 6 75 76 78 81 A drug of choice for treatment of uncomplicated UTIs caused by E. faecalis;81 consider high incidence of amoxicillin-resistant E. coli and other Enterobacteriaceae.6

Gonorrhea

Previously used for treatment of acute uncomplicated gonorrhea (anogenital and urethral) caused by susceptible Neisseria gonorrhoeae.1 6 184 However, CDC has not recommended use of penicillins for treatment of gonorrhea for over 30 years because of the widespread prevalence of penicillinase-producing strains of N. gonorrhoeae (PPNG).344

Typhoid Fever and other Salmonella Infections

Alternative for treatment of typhoid fever† [off-label] (enteric fever) caused by susceptible Salmonella typhi.6 57 64 66 68 81 190 Drugs of choice are fluoroquinolones and third generation cephalosporins (e.g., ceftriaxone, cefotaxime);81 190 consider that multidrug-resistant strains of S. typhi (strains resistant to ampicillin, amoxicillin, chloramphenicol, and/or co-trimoxazole) reported with increasing frequency.102 190

Treatment of chronic carriers of S. typhi† [off-label]; drugs of choice are fluoroquinolones (e.g., ciprofloxacin), ampicillin, or amoxicillin (with probenecid).6 62 63 65 67 81

Alternative for treatment of gastroenteritis caused by nontyphoidal Salmonella† [off-label].190 Anti-infectives not indicated in otherwise healthy individuals with uncomplicated (noninvasive) gastroenteritis, but recommended if gastroenteritis is severe and in those at increased risk of invasive disease (e.g., <6 months or >50 years of age; hemoglobinopathies, severe atherosclerosis, valvular heart disease, prostheses, uremia, chronic GI disease, severe colitis; immunocompromised because of malignancy, immunosuppressive therapy, HIV infection).81 120 121 190 Drugs of choice are fluoroquinolones, third generation cephalosporins (cefotaxime, ceftriaxone), ampicillin, amoxicillin, co-trimoxazole, or chloramphenicol, depending on in vitro susceptibility.81 120 121 190

Helicobacter pylori Infection and Duodenal Ulcer Disease

Treatment of Helicobacter pylori infection and duodenal ulcer disease (active or 1-year history of duodenal ulcer);1 168 172 173 174 eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.1 107 116 119 122 168 172 173

Used in a multidrug regimen that includes amoxicillin, clarithromycin, and either lansoprazole or omeprazole (triple therapy).1 81 107 168 169 172 173 174 175 Used with lansoprazole (dual therapy) in those allergic to or intolerant of clarithromycin or when clarithromycin resistance is suspected.1 168 169

Lyme Disease

Treatment of erythema migrans and certain other manifestations of Lyme disease† [off-label].292 329 331

IDSA, AAP, American Academy of Neurology (AAN), American College of Rheumatology (ACR), and others consider amoxicillin a drug of choice for treatment of erythema migrans†.292 329 331 Also considered a drug of choice when an oral regimen is indicated for the treatment of Lyme carditis† or Lyme arthritis†.329 331 179 181 182 185 186 232 238

Chlamydial Infections

Treatment of uncomplicated urethritis and cervicitis caused by Chlamydia trachomatis in pregnant women†.81 157 190 344 CDC recommends azithromycin as drug of choice and amoxicillin as alternative for treatment of urogenital chlamydial infections in pregnant women.344

Prevention of Bacterial Endocarditis

Prevention of α-hemolytic (viridans group) bacterial endocarditis† in patients undergoing certain dental procedures (i.e., procedures that involve manipulation of gingival tissue or periapical region of teeth or perforation of oral mucosa) or certain invasive respiratory tract procedures (i.e., procedures involving incision or biopsy of respiratory mucosa) who have certain cardiac conditions that put them at highest risk of adverse outcomes from endocarditis.69 72 97 99 100 101 451 AHA recommends amoxicillin as drug of choice for such prophylaxis.451

Anti-infective prophylaxis solely for prevention of bacterial endocarditis no longer recommended by AHA for patients undergoing GU or GI procedures.451

Consult most recent AHA recommendations for information on which cardiac conditions are associated with highest risk of adverse outcomes from endocarditis and specific recommendations regarding use of prophylaxis to prevent endocarditis in these patients.451

Prevention of S. pneumoniae Infections in Asplenic Individuals

Prevention of invasive S. pneumoniae infections in children with anatomic or functional asplenia† (e.g., congenital, resulting from sickle cell disease or surgery)190 or children with malignant neoplasms or thalassemia.190

Oral penicillin V usually drug of choice;74 190 some experts recommend amoxicillin.190

Children at increased risk for pneumococcal infections should receive age-appropriate vaccination with pneumococcal 13-valent conjugate vaccine (PCV13) and pneumococcal 23-valent polysaccharide vaccine (PPSV23).190 243 Long-term anti-infective prophylaxis recommended for children with functional or anatomic asplenia regardless of vaccination status.74 190 243

Anthrax

Alternative for postexposure prophylaxis of anthrax† following exposure to Bacillus anthracis spores (inhalational anthrax).190 228 229 231 233 235 236 239 671 672 673 Ciprofloxacin or doxycycline are initial drugs of choice for prophylaxis following suspected or confirmed exposure to aerosolized anthrax spores, including exposures that occur in the context of biologic warfare or bioterrorism.190 231 235 671 672 673 If penicillin susceptibility confirmed, consideration can be given to changing prophylaxis to a penicillin (oral amoxicillin or penicillin V) in infants and children, pregnant or lactating women, or when drugs of choice not tolerated or not available;671 672 673 amoxicillin may be preferred, especially in infants and children.671

Alternative for treatment of inhalational anthrax† when a parenteral regimen not available (e.g., when there are supply or logistic problems in a mass-casualty setting).231

Alternative for treatment of cutaneous anthrax† caused by susceptible B. anthracis.231 671 672 673 If cutaneous anthrax occurs in the context of biologic warfare or bioterrorism, initial drugs of choice are ciprofloxacin or doxycycline.231 671 672 673 If penicillin susceptibility confirmed, consideration can be given to changing to a penicillin (oral amoxicillin or penicillin V) in infants and children, pregnant or lactating women, or when drugs of choice not tolerated or not available;671 672 673 amoxicillin may be preferred, especially in infants and children.671

Amoxicillin Dosage and Administration

Administration

Oral Administration

Administer orally without regard to meals.1 4 10 22 29 38 40

Following reconstitution, the required amount of oral suspension should be placed directly on the child’s tongue for swallowing.1 Alternatively, the required amount of suspension can be added to infant formula, milk, fruit juice, water, ginger ale, or cold drinks and these fluids taken immediately and completely consumed.1

For most infections, continue therapy for at least 48–72 hours after patient becomes asymptomatic or evidence that the infection is eradicated is obtained.1 The drug should be given for at least 10 days for treatment of infections caused by S. pyogenes (group A β-hemolytic streptococci).1

Reconstitution

Reconstitute oral suspension at the time of dispensing.1 Tap bottle to thoroughly loosen powder and then add the amount of water specified on the bottle in 2 portions; agitate vigorously after each addition.1

Agitate suspension well prior to administration of each dose.1

Dosage

Available as the trihydrate;1 dosage expressed in terms of anhydrous amoxicillin.1

Pediatric Patients

General Pediatric Dosage
Oral

Neonates and infants ≤12 weeks (3 months) of age: Manufacturer states dosage up to 30 mg/kg daily can be given in divided doses every 12 hours.1

Children ≥3 months of age weighing ≥40 kg: Manufacturer states use usual adult dosage.1

Children beyond neonatal period with mild to moderate infections: AAP recommends 25–50 mg/kg daily given in 3 divided doses.292

Children beyond neonatal period with severe infections: AAP states that 80–100 mg/kg daily given in 3 divided doses can be used for step-down therapy.292 For highly susceptible pathogens, 90 mg/kg daily given in 2 divided doses can be used.292

Otitis Media
Treatment of Acute Otitis Media (AOM)
Oral

80–90 mg/kg daily given in 2 or 3 divided doses† recommended by AAP, AAFP, CDC, and others.190 200 201 205 215 683

Usual duration is 10 days;190 200 201 205 215 optimal duration uncertain.683 AAP recommends 10 days of treatment in those <2 years of age and in those with severe symptoms.683 For mild to moderate AOM in older children, AAP states 7- and 10-day regimens appear equally effective in those 2–5 years of age and a duration of 5–7 days may be adequate in those ≥6 years of age.683

Pharyngitis and Tonsillitis
Oral

45 mg/kg daily in 2 divided doses or 40 mg/kg daily in 3 divided doses for 10 days recommended by manufacturer.1

AHA and AAP recommend 50 mg/kg (up to 1 g) once daily for 10 days.292 375

IDSA recommends 50 mg/kg (up to 1 g) once daily for 10 days or 25 mg/kg (up to 500 mg) twice daily for 10 days.580

Ear, Nose, and Throat Infections
Oral

25 mg/kg daily in divided doses every 12 hours or 20 mg/kg daily in divided doses every 8 hours for mild to moderate infections.1

45 mg/kg daily in divided doses every 12 hours or 40 mg/kg in divided doses every 8 hours for severe infections.1

Respiratory Tract Infections
Oral

45 mg/kg daily in divided doses every 12 hours or 40 mg/kg daily in divided doses every 8 hours for mild, moderate, or severe lower respiratory tract infections.1

Skin and Skin Structure Infections
Oral

25 mg/kg daily in divided doses every 12 hours or 20 mg/kg daily in divided doses every 8 hours for mild to moderate infections.1

45 mg/kg daily in divided doses every 12 hours or 40 mg/kg daily in divided doses every 8 hours for severe infections or those caused by less susceptible bacteria.1

Urinary Tract Infections (UTIs)
Oral

25 mg/kg daily in divided doses every 12 hours or 20 mg/kg daily in divided doses every 8 hours for mild to moderate infections.1

45 mg/kg daily in divided doses every 12 hours or 40 mg/kg daily in divided doses every 8 hours for severe infections or those caused by less susceptible bacteria.1

Gonorrhea
Oral

Prepubertal children ≥2 years of age: Manufacturer recommends 50 mg/kg as a single dose given with a single dose of probenecid (25 mg/kg) recommended by manufacturer.1

No longer recommended for gonorrhea by CDC.344

Lyme Disease†
Erythema Migrans†
Oral

50 mg/kg daily in 3 divided doses (maximum 500 mg per dose) for 14 days.292 329 331

Lyme Carditis†
Oral

50 mg/kg daily in 3 divided doses (maximum 500 mg per dose) for 14–21 days.329 331 Use in outpatients when an IV regimen not required or as follow-up after an initial IV regimen.329 331

Lyme Arthritis†
Oral

50 mg/kg daily in 3 divided doses (maximum 500 mg per dose) for 28 days.329 331

Prevention of Bacterial Endocarditis†
Patients Undergoing Certain Dental or Respiratory Tract Procedures†
Oral

50 mg/kg given as a single dose 30–60 minutes prior to the procedure.451

Prevention of S. pneumoniae Infections in Asplenic Individuals†
Oral

20 mg/kg daily in children with anatomic or functional asplenia.190

In infants with sickle cell anemia, initiate prophylaxis as soon as diagnosis is established (preferably by 2 months of age);74 190 continue until approximately 5 years of age.74 190 243 Appropriate duration in children with asplenia from other causes unknown;190 some experts recommend that asplenic children at high risk receive prophylaxis throughout childhood and into adulthood.190

Anthrax†
Postexposure Prophylaxis of Anthrax†
Oral

Full-term neonates ≤4 weeks of age: AAP recommends 75 mg/kg daily given in divided doses every 8 hours.671

Preterm neonates (gestational age 32–37 weeks): AAP recommends 50 mg/kg daily given in divided doses every 12 hours in those ≤1 week of age and 75 mg/kg daily given in divided doses every 8 hours in those 1–4 weeks of age.671

Infants and children ≥1 month of age: AAP recommends 75 mg/kg daily (up to 1 g daily) given in divided doses every 8 hours.671

Children: Some experts recommend 80 mg/kg daily given in divided doses every 8 hours in those weighing <20 kg and 500 mg every 8 hours in those weighing ≥20 kg.231

Use only if penicillin-susceptible B. anthracis involved.671

Total duration of anti-infective prophylaxis should be ≥60 days.190 231 233 239 671

Treatment of Inhalational Anthrax†
Oral

Full-term neonates ≤4 weeks of age for follow-up after initial parenteral regimen: AAP recommends 75 mg/kg daily given in divided doses every 8 hours in conjunction with other anti-infectives.671

Preterm neonates (gestational age 32–37 weeks) for follow-up after initial parenteral regimen: AAP recommends 50 mg/kg daily given in divided doses every 12 hours in those ≤1 week of age and 75 mg/kg daily given in divided doses every 8 hours in those 1–4 weeks of age in conjunction with other anti-infectives.671

Infants and children ≥1 month of age for follow-up after initial parenteral regimen: 75 mg/kg daily (up to 1 g daily) given in divided doses every 8 hours in conjunction with other anti-infectives.671

Children with inhalational anthrax in mass casualty setting when parenteral anti-infectives not available: Some experts recommend 80 mg/kg daily given in divided doses every 8 hours in those weighing <20 kg and 500 mg every 8 hours in those weighing ≥20 kg.231

Recommended dosages are for infections that occur in the context of biologic warfare or bioterrorism231 671 and when meningitis can be ruled out.671

Use only if infection known to be caused by penicillin-susceptible B. anthracis.671

Total duration of anti-infective treatment should be 60 days.231 671

Treatment of Cutaneous Anthrax†
Oral

Full-term neonates ≤4 weeks of age with cutaneous anthrax without systemic involvement: AAP recommends 75 mg/kg daily given in divided doses every 8 hours.671

Preterm neonates (gestational age 32–37 weeks) with cutaneous anthrax without systemic involvement: AAP recommends 50 mg/kg daily given in divided doses every 12 hours in those ≤1 week of age and 75 mg/kg daily given in divided doses every 8 hours in those 1–4 weeks of age.671

Infants and children ≥1 month of age with cutaneous anthrax without systemic involvement: AAP recommends 75 mg/kg daily (up to 1 g daily) given in divided doses every 8 hours.671

Children: Some experts recommend 80 mg/kg daily (up to 1.5 g daily) given in divided doses every 8 hours.231

Recommended dosages are for infections that occur in the context of biologic warfare or bioterrorism.231 671

Use only if infection known to be caused by penicillin-susceptible B. anthracis.671

Although 7–10 days may be adequate if cutaneous anthrax occurred as the result of natural or endemic exposure to anthrax,231 234 CDC, AAP, and others recommend 60 days of anti-infective treatment if cutaneous anthrax occurred as the result of exposure to aerosolized anthrax spores (e.g., in context of biologic warfare or bioterrorism).231 234 671

Adults

Pharyngitis and Tonsillitis
Oral

AHA recommends 50 mg/kg (up to 1 g) once daily for 10 days.375

IDSA recommends 50 mg/kg (up to 1 g) once daily for 10 days or 25 mg/kg (up to 500 mg) twice daily for 10 days.580

Ear, Nose, and Throat Infections
Oral

500 mg every 12 hours or 250 mg every 8 hours for mild to moderate infections.1

875 mg every 12 hours or 500 mg every 8 hours for severe infections or those caused by less susceptible bacteria.1

Respiratory Tract Infections
Oral

875 mg every 12 hours or 500 mg every 8 hours for mild, moderate, or severe lower respiratory tract infections.1

Skin and Skin Structure Infections
Oral

500 mg every 12 hours or 250 mg every 8 hours for mild to moderate infections.1

875 mg every 12 hours or 500 mg every 8 hours for severe infections or those caused by less susceptible bacteria.1

Urinary Tract Infections (UTIs)
Oral

500 mg every 12 hours or 250 mg every 8 hours for mild to moderate infections.1

875 mg every 12 hours or 500 mg every 8 hours for severe infections or those caused by less susceptible bacteria.1

Gonorrhea
Oral

Manufacturer recommends 3 g as a single dose.1

No longer recommended for gonorrhea by CDC.344

Typhoid Fever†
Oral

100 mg/kg daily or 1–1.5 g every 6 hours for 14 days.6

Helicobacter pylori Infection and Duodenal Ulcer Disease
Oral

1 g 2 times daily for 10 or 14 days given in conjunction with clarithromycin and either lansoprazole or omeprazole (triple therapy).1 168 172 173 174

1 g 3 times daily for 14 days given in conjunction with lansoprazole (dual therapy).1 168

Lyme Disease†
Erythema Migrans†
Oral

500 mg 3 times daily for 14 days.329 331

Lyme Carditis†
Oral

500 mg 3 times daily for 14–21 days.329 331 Use in outpatients when an IV regimen not required or as follow-up after an initial IV regimen.329 331

Lyme Arthritis†
Oral

500 mg 3 times daily for 28 days.329 331

Chlamydial Infections†
Oral

500 mg 3 times daily for 7 days for treatment of chlamydial infections in pregnant women.344

Prevention of Bacterial Endocarditis†
Patients Undergoing Certain Dental or Respiratory Tract Procedures†
Oral

2 g as a single dose given 30–60 minutes prior to the procedure.451

Anthrax†
Postexposure Prophylaxis of Anthrax†
Oral

500 mg every 8 hours has been recommended.231 233 236

1 g every 8 hours recommended by CDC for adults (including pregnant and postpartum women) if exposure occurred in the context of biologic warfare or bioterrorism.672

Use only if penicillin-susceptible B. anthracis involved.672 673

Total duration of anti-infective prophylaxis should be ≥60 days.190 231 233 239 672

Treatment of Inhalational Anthrax†
Oral

Inhalational anthrax in mass casualty setting when parenteral anti-infectives not available: 500 mg every 8 hours for 60 days.231

Treatment of Cutaneous Anthrax†
Oral

500 mg every 8 hours has been recommended.231

1 g every 8 hours recommended by CDC for adults (including pregnant and postpartum women) for cutaneous anthrax without systemic involvement if infection occurred in the context of biologic warfare or bioterrorism.672

Use only if infection known to be caused by penicillin-susceptible B. anthracis.672 673

Although 7–10 days may be adequate if cutaneous anthrax occurred as the result of natural or endemic exposure to anthrax,231 234 CDC and others recommend 60 days of anti-infective treatment if cutaneous anthrax occurred as the result of exposure to aerosolized anthrax spores (e.g., in context of biologic warfare or bioterrorism).231 234 672

Prescribing Limits

Pediatric Patients

Neonates and Infants ≤12 weeks (3 Months) of Age
Oral

Maximum 30 mg/kg daily in divided doses every 12 hours.1

Special Populations

Renal Impairment

Dosage adjustment necessary in severe renal impairment.1 6 41 82 83

Do not use 875-mg tablets in those with severe renal impairment and GFR <30 mL/minute.1

Dosage recommendations not available for pediatric patients with renal impairment.1

Dosage for Adults with Renal Impairment

GFR (mL/min)

Daily Dosage

10–30

250 or 500 mg every 12 hours depending on infection severity1

<10

250 or 500 mg every 24 hours depending on infection severity1

Hemodialysis Patients

250 or 500 mg every 24 hours depending on infection severity; with an additional dose both during and at the end of dialysis1
Detailed Amoxicillin dosage information

Cautions for Amoxicillin

Contraindications

Warnings/Precautions

Warnings

Superinfection/Clostridioides difficile-associated Colitis

Possible emergence and overgrowth of nonsusceptible bacteria or fungi.1 21 Discontinue and institute appropriate therapy if superinfection occurs.1

Treatment with anti-infectives alters normal colon flora and may permit overgrowth of C. difficile.1 302 C. difficile infection (CDI) and C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives and may range in severity from mild diarrhea to fatal colitis.302 Consider CDAD if diarrhea develops during or after therapy and manage accordingly.1 302

If CDAD suspected or confirmed, discontinue anti-infectives not directed against C. difficile as soon as possible.302 Initiate appropriate anti-infective therapy directed against C. difficile (e.g., fidaxomicin, vancomycin, metronidazole), appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), and surgical evaluation as clinically indicated.1 302

Sensitivity Reactions

Hypersensitivity Reactions

Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, reported with penicillins.1 6 51 53 55

Prior to initiation of therapy, make careful inquiry regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other drugs.1 Partial cross-allergenicity occurs among penicillins and other β-lactam antibiotics including cephalosporins and cephamycins.1 6

If a severe hypersensitivity reaction occurs, discontinue immediately and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).1

General Precautions

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of amoxicillin and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.1

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.1 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.1

Hepatic Effects

Moderate increases in serum AST and/or ALT reported.1

Hepatic dysfunction, including cholestatic jaundice, hepatic cholestasis, and acute cytolytic hepatitis reported.1

Assess hepatic function periodically during prolonged therapy.1

Renal Effects

Assess renal function periodically during prolonged therapy.1

Hematologic Effects

Adverse hematologic effects (e.g., anemia, hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia, thrombocytopenic purpura) reported with penicillins.1 Usually reversible when drug discontinued; may be a hypersensitivity reaction.1

Assess hematologic function periodically during prolonged therapy.1

Mononucleosis

Possible increased risk of rash in patients with mononucleosis; use in these patients not recommended.4 29 54 60

Phenylketonuria

200- and 400-mg chewable tablets contain aspartame (NutraSweet), which is metabolized in the GI tract to provide 1.82 or 3.64 mg of phenylalanine, respectively.1 3

Oral suspensions do not contain aspartame and can be used in individuals with phenylketonuria (i.e., homozygous genetic deficiency of phenylalanine hydroxylase) and other individuals who must restrict their intake of phenylalanine.1

Specific Populations

Pregnancy

Category B.

Recommended as an alternative for various indications in pregnant women (e.g., treatment of chlamydial infections†,344 treatment of Lyme disease†,88 181 182 190 191 postexposure prophylaxis or treatment of anthrax†).672

Lactation

Distributed into milk; use with caution.1 4 6 26 49

Use in a breast-feeding woman may result in sensitization of infants.1

Recommended as an alternative for postexposure prophylaxis or treatment of anthrax† in women who are breast-feeding.239

Pediatric Use

Renal clearance of amoxicillin may be delayed in neonates and young infants because of incompletely developed renal function.20 27 32 62 128

Neonates and infants ≤12 weeks (3 months) of age should receive no more than 30 mg/kg daily given in divided doses every 12 hours.1

Tooth discoloration (brown, yellow, gray) reported rarely, most frequently in pediatric patients.1 Brushing or dental cleaning reduces or eliminates discoloration in most cases.1

Geriatric Use

Renal clearance may be decreased.

Hepatic Impairment

Assess hepatic function periodically during prolonged therapy.1

Renal Impairment

Assess renal function periodically during prolonged therapy.1

Dosage adjustments necessary in severe renal impairment.1 41 82 83

Common Adverse Effects

Adverse GI effects (e.g., nausea, vomiting, diarrhea), hypersensitivity reactions (e.g., rash).1 4 52 142

Drug Interactions

Specific Drugs and Laboratory Tests

Drug

Interaction

Comments

Allopurinol

Possible increased incidence of rash;59 61 84 reported with ampicillin but no data regarding amoxicillin59 61 84

Unclear whether potentiation of rash is caused by allopurinol or hyperuricemia present in these patients59 61 84

Chloramphenicol

In vitro evidence of antagonism1

Clinical importance unclear1

Clavulanic acid

In vitro and in vivo synergistic bactericidal effect13 14 15 16 84 85 86 87 127

Used to therapeutic advantage in infections caused by β-lactamase-producing bacteria;84 commercially available in fixed combination with clavulanate potassium84

Macrolides

In vitro evidence of antagonism1

Clinical importance unclear1

Methotrexate

Possible decreased renal clearance of methotrexate;171 possible increased methotrexate concentrations and hematologic and GI toxicity171

Monitor closely if used concomitantly171

Probenecid

Decreased renal tubular secretion of amoxicillin;1 23 24 34 increased and prolonged amoxicillin concentrations may occur1 23 24 34

Sulfonamides

In vitro evidence of antagonism1

Clinical importance unclear1

Tests for glucose

Possible false-positive reactions in urine glucose tests using Clinitest, Benedict’s solution, or Fehling’s solution;1 reported with ampicillin but no data regarding amoxicillin1

Use glucose tests based on enzymatic glucose oxidase reactions (e.g., Clinistix, Tes-Tape)1

Tetracyclines

In vitro evidence of antagonism1

Clinical importance unclear1
Amoxicillin drug interactions (more detail)

Amoxicillin Pharmacokinetics

Absorption

Bioavailability

74–92% of an oral dose absorbed from GI tract.4 17 28 44 62

Peak serum concentrations usually attained within 1–2 hours.1 6 23 36 40 47

A 400-mg chewable tablet is bioequivalent to 5 mL of the oral suspension containing 400 mg/5 mL.1

Food

Food has minimal or no effect on bioavailability of oral amoxicillin.4 6 10 22 29 38 40 62

Special Populations

Oral absorption delayed in neonates compared with older children and adults;20 27 peak concentrations attained within 3–4.5 hours in neonates.20 27

Distribution

Extent

Readily distributed into most tissues and fluids1 following oral administration, including lungs,6 48 bronchial secretions,19 maxillary sinus secretions,4 bile,6 48 pleural fluid,6 sputum,4 6 30 and middle ear fluid.4 56 203

Only low concentrations attained in CSF.6 33 37

Crosses the placenta4 6 and is distributed into human milk.4 6 49

Plasma Protein Binding

17–20%.1 6 9 29 45 62

Elimination

Metabolism

Probably metabolized to some extent in the liver.6 28 36 42

Elimination Route

Eliminated principally in urine by both glomerular filtration and tubular secretion.6

Approximately 50–80% of amoxicillin dose excreted unchanged in urine.1 6

Half-life

1–1.4 hours.1 17 21 29 36 43 46 50

Special Populations

Serum concentrations increased and half-life prolonged in patients with renal impairment.17 25 31 41 50 62

Renal clearance may be delayed in neonates and young infants because of incompletely developed renal function.20 27 32 128

Stability

Storage

Oral

Capsules

≤20°C.1

For Suspension

250 mg/5 mL: ≤20°C.1 Following reconstitution, refrigerate (preferable but not required) and discard after 14 days.1

200 or 400 mg/5 mL: ≤25°C.1 Following reconstitution, refrigerate (preferable but not required) and discard after 14 days.1

Tablets

200- and 400-mg chewable tablets and 500- or 875-mg film-coated tablets: ≤25°C.1

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Amoxicillin (Trihydrate)

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

250 mg (of amoxicillin)*

Amoxicillin Capsules

Amoxil

GlaxoSmithKline

500 mg (of amoxicillin)*

Amoxicillin Capsules

Amoxil

GlaxoSmithKline

For suspension

125 mg (of amoxicillin) per 5 mL*

Amoxicillin for Suspension

Amoxil

GlaxoSmithKline

Larotid

200 mg (of amoxicillin) per 5 mL*

Amoxicillin for Suspension

250 mg (of amoxicillin) per 5 mL*

Amoxicillin for Suspension

Amoxil

GlaxoSmithKline

Larotid

50 mg (of amoxicillin) per mL*

Amoxicillin for Suspension

Amoxil

GlaxoSmithKline

400 mg (of amoxicillin) per 5 mL*

Amoxicillin for Suspension

Amoxil

GlaxoSmithKline

Tablets, chewable

125 mg (of amoxicillin)*

Amoxicillin Chewable Tablets

250 mg (of amoxicillin)*

Amoxicillin Chewable Tablets

Tablets, film-coated

500 mg (of amoxicillin)*

Amoxicillin Tablets

875 mg (of amoxicillin)*

Amoxicillin Tablets

AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. GlaxoSmithKline. Amoxil (amoxicillin) capsules, chewable tablets, and powder for oral suspension prescribing information. Research Triangle Park, NC; 2004 Jun.

2. Hou JP, Poole JW. β-Lactam antibiotics: their physiochemical properties and biological activities in relation to structure. J Pharm Sci. 1971; 60:503-27. http://www.ncbi.nlm.nih.gov/pubmed/4336386?dopt=AbstractPlus

3. Wilkowske CJ. The penicillins. Mayo Clin Proc. 1977; 52:616-24. http://www.ncbi.nlm.nih.gov/pubmed/242733?dopt=AbstractPlus

4. Brogden RN, Speight TM, Avery GS. Amoxycillin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs. 1975; 9:88-140. http://www.ncbi.nlm.nih.gov/pubmed/1126306?dopt=AbstractPlus

5. Brogden RN, Heel RC, Speight TM et al. Amoxycillin injectable: a review of its antibacterial spectrum, pharmacokinetics and therapeutic use. Drugs. 1979; 18:169-84. http://www.ncbi.nlm.nih.gov/pubmed/387371?dopt=AbstractPlus

6. Kucers A, Crowe S, Grayson ML et al, eds. The use of antibiotics. A clinical review of antibacterial, antifungal, and antiviral drugs. 5th ed. Jordan Hill, Oxford: Butterworth-Heinemann; 1997: 134-42.

7. Rolinson GN, Macdonald AC, Wilson DA. Bactericidal action of β-lactam antibiotics on Escherichia coli with particular reference to ampicillin and amoxycillin. J Antimicrob Chemother. 1977; 3:541-53. http://www.ncbi.nlm.nih.gov/pubmed/340439?dopt=AbstractPlus

8. Lorian V, ed. Antibiotics in laboratory medicine. Baltimore: Williams & Wilkins; 1980:298-341, 418-73, 607-722.

9. Sutherland R, Croydon EA, Rolinson GN. Amoxycillin: a new semi-synthetic penicillin. Br Med J. 1972; 3:13-6. http://www.ncbi.nlm.nih.gov/pubmed/4402672?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1788503&blobtype=pdf

10. Rolinson GN. Laboratory evaluation of amoxicillin. J Infect Dis. 1974; 129(Suppl):S139-45. http://www.ncbi.nlm.nih.gov/pubmed/4601188?dopt=AbstractPlus

11. Neu HC. Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis. 1974; 129(Suppl):S123-31.

12. Rocco V, Overturf G. Chloramphenicol inhibition of the bactericidal effect of ampicillin against Haemophilus influenzae. Antimicrob Agents Chemother. 1982; 21:349-51. http://www.ncbi.nlm.nih.gov/pubmed/6978674?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=181888&blobtype=pdf

13. Wise R, Andrews JM, Bedford KA. In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother. 1978; 13:389-93. http://www.ncbi.nlm.nih.gov/pubmed/122520?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352250&blobtype=pdf

14. Hunter PA, Coleman K, Fisher J et al. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother. 1980; 6:455-70. http://www.ncbi.nlm.nih.gov/pubmed/6968746?dopt=AbstractPlus

15. Matsuura M, Nakazawa H, Hashimoto T et al. Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains. Antimicrob Agents Chemother. 1980; 17:908-11. http://www.ncbi.nlm.nih.gov/pubmed/6967713?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=283901&blobtype=pdf

16. Brogden RN, Carmine A, Heel RC et al. Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs. 1981; 22:337-62. http://www.ncbi.nlm.nih.gov/pubmed/7037354?dopt=AbstractPlus

17. Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clin Pharmacokinet. 1976; 1:297-308. http://www.ncbi.nlm.nih.gov/pubmed/797501?dopt=AbstractPlus

18. Ullmann U, Wurst W. Antibacterial active components in human urine after administration of penicillins. Infection. 1979; 7:187-9. http://www.ncbi.nlm.nih.gov/pubmed/511336?dopt=AbstractPlus

19. Bergogne-Berezin E, Morel C, Benard Y et al. Pharmacokinetic study of β-lactam antibiotics in bronchial secretions. Scand J Infect Dis. 1978; 14(Suppl):267-72.

20. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet. 1980; 5:485-527. http://www.ncbi.nlm.nih.gov/pubmed/7002417?dopt=AbstractPlus

21. Selwyn S. Applied pharmacology, adverse effects and drug interactions. In: Selwyn S, ed. The beta-lactam antibiotics: penicillins and cephalosporins in perspective. London: Hodder and Stoughton; 1980:91-126.

22. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet. 1978:3:337-51.

23. Barbhaiya R, Thin RN, Turner P et al. Clinical pharmacological studies of amoxycillin: effect of probenecid. Br J Vener Dis. 1979; 55:211-3. http://www.ncbi.nlm.nih.gov/pubmed/466384?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1045632&blobtype=pdf

24. Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther. 1968; 9:345-9. http://www.ncbi.nlm.nih.gov/pubmed/5649987?dopt=AbstractPlus

25. Giusti DL. A review of the clinical use of antimicrobial agents in patients with renal and hepatic insufficiency: the penicillins. Drug Intell Clin Pharm. 1973; 7:62-74.

26. Anderson PO. Drugs and breast feeding—a review. Drug Intell Clin Pharm. 1977; 11:208-23.

27. Cohen MD, Raeburn JA, Devine J et al. Pharmacology of some oral penicillins in the newborn infant. Arch Dis Child. 1975; 50:230-4. http://www.ncbi.nlm.nih.gov/pubmed/1147656?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1544517&blobtype=pdf

28. Cole M, Kening MD, Hewitt VA. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob Agents Chemother. 1973; 3:463-8. http://www.ncbi.nlm.nih.gov/pubmed/4364176?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=444435&blobtype=pdf

29. Brogden RN, Speight TM, Avery GS. Amoxycillin: a preliminary report of its pharmacokinetic properties and therapeutic efficacy. Drugs. 1974; 7:326-36. http://www.ncbi.nlm.nih.gov/pubmed/4604079?dopt=AbstractPlus

30. Davies B, Maesen F. Serum and sputum antibiotic levels after ampicillin, amoxycillin and bacampicillin in chronic bronchitis patients. Infection. 1979; 7(Suppl 5):S465-8.

31. Francke EL, Appel GB, Neu HC. Kinetics of intravenous amoxicillin in patients on long-term dialysis. Clin Pharmacol Ther. 1979; 26:31-5. http://www.ncbi.nlm.nih.gov/pubmed/445959?dopt=AbstractPlus

32. Rudoy RC, Goto N, Pettit D et al. Pharmacokinetics of intravenous amoxicillin in pediatric patients. Antimicrob Agents Chemother. 1979; 15:628-9. http://www.ncbi.nlm.nih.gov/pubmed/464594?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352722&blobtype=pdf

33. Strausbaugh LJ, Girgis NI, Mikhail IA et al. Penetration of amoxicillin into cerebrospinal fluid. Antimicrob Agents Chemother. 1978; 14:899-902. http://www.ncbi.nlm.nih.gov/pubmed/742877?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352576&blobtype=pdf

34. Craft JC, Feldman WE, Nelson JD. Clinicopharmacological evaluation of amoxicillin and probenecid against bacterial meningitis. Antimicrob Agents Chemother. 1979; 16:346-52. http://www.ncbi.nlm.nih.gov/pubmed/507789?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352859&blobtype=pdf

35. Shvartzman P, Tabenkin H, Rosentzqaig A et al. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ. 1993; 306:1170-2. http://www.ncbi.nlm.nih.gov/pubmed/8499823?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1677641&blobtype=pdf

36. Arancibia A, Guttmann J, Gonzalez G et al. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother. 1980; 17:199-202. http://www.ncbi.nlm.nih.gov/pubmed/7387142?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=283758&blobtype=pdf

37. Clumeck N, Thys JP, Vanhoof R et al. Amoxicillin entry into human cerebrospinal fluid: comparison with ampicillin. Antimicrob Agents Chemother. 1978; 14:531-2. http://www.ncbi.nlm.nih.gov/pubmed/102244?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352502&blobtype=pdf

38. Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother. 1978; 14:539-43. http://www.ncbi.nlm.nih.gov/pubmed/363052?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352504&blobtype=pdf

39. Hayes CS, Williamson H. Management of group A beta-hemolytic streptococcal pharyngitis. Am Fam Physician. 2001; 63:1557-64. http://www.ncbi.nlm.nih.gov/pubmed/11327431?dopt=AbstractPlus

40. Welling PG, Huang H, Kock PA et al. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subject. J Pharm Sci. 1977; 66:549-52. http://www.ncbi.nlm.nih.gov/pubmed/323461?dopt=AbstractPlus

41. Oe PL, Simonian S, Verhoef J. Pharmacokinetics of the new penicillins. Chemotherapy. 1973; 19:279-88. http://www.ncbi.nlm.nih.gov/pubmed/4787741?dopt=AbstractPlus

42. Graber H, Perenyi T, Arr M et al. On human biotransformation of some penicillins. Int J Clin Pharmacol. 1976; 14:284-9.

43. Gordon RC, Regamey C, Kirby WM. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother. 1972; 1:504-7. http://www.ncbi.nlm.nih.gov/pubmed/4680813?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=444250&blobtype=pdf

44. Zarowny D, Ogilvie R, Tamblyn D et al. Pharmacokinetics of amoxicillin. Clin Pharmacol Ther. 1974; 16:1045-51. http://www.ncbi.nlm.nih.gov/pubmed/4433471?dopt=AbstractPlus

45. Tan JS, Bannister T, Phair JP. Levels of amoxicillin and ampicillin in human serum and interstitial fluid. J Infect Dis. 1974; 129(Suppl):S146-8. http://www.ncbi.nlm.nih.gov/pubmed/4601189?dopt=AbstractPlus

46. Kirby WM, Gordon RC, Regamey C. The pharmacology of orally administered amoxicillin and ampicillin. J Infect Dis. 1974; 129(Suppl):S154-5.

47. Lode H, Janisch P, Kupper G et al. Comparative clinical pharmacology of three ampicillins and amoxicillin administered orally. J Infect Dis. 1974; 129(Suppl):S156-70. http://www.ncbi.nlm.nih.gov/pubmed/4834960?dopt=AbstractPlus

48. Kiss IJ, Farago E, Schnitzler J et al. Amoxycillin levels in human serum, bile, gallbladder, lung, and liver tissue. Int J Clin Pharmacol Ther Toxicol. 1981; 19:69-74. http://www.ncbi.nlm.nih.gov/pubmed/7216553?dopt=AbstractPlus

49. Kafetzis DA, Siafas CA, Georgakopoulos PA et al. Passage of cephalosporins and amoxicillin into the breast milk. Acta Paediatr Scand. 1981; 70:285-8. http://www.ncbi.nlm.nih.gov/pubmed/7246123?dopt=AbstractPlus

50. Arancibia A, Droguett MT, Fuentes G et al. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. Int J Clin Pharmacol Ther Toxicol. 1982; 20:447-53. http://www.ncbi.nlm.nih.gov/pubmed/7141752?dopt=AbstractPlus

51. Idsoe O, Guthe T, Willcox RR et al. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ. 1968; 38:159-88. http://www.ncbi.nlm.nih.gov/pubmed/5302296?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2554321&blobtype=pdf

52. Nordbring F. Review of side-effects of aminopenicillins. Infection. 1979; 7(Suppl 5):S503-6. http://www.ncbi.nlm.nih.gov/pubmed/511364?dopt=AbstractPlus

53. Erffmeyer JE. Adverse reactions to penicillin. Ann Allergy. 1981; 47:288-300. http://www.ncbi.nlm.nih.gov/pubmed/6171185?dopt=AbstractPlus

54. Copeman PW, Scrivener R. Amoxycillin rash. Br Med J. 1977; 1:1354. http://www.ncbi.nlm.nih.gov/pubmed/861632?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1607178&blobtype=pdf

55. Isbister JP. Penicillin allergy: a review of the immunological and clinical aspects. Med J Aust. 1971; 1:1067-74. http://www.ncbi.nlm.nih.gov/pubmed/4398272?dopt=AbstractPlus

56. Klimek JJ, Nightingale C, Lehmann WB et al. Comparison of concentrations of amoxicillin and ampicillin in serum and middle ear fluid of children with chronic otitis media. J Infect Dis. 1977; 135:999-1002. http://www.ncbi.nlm.nih.gov/pubmed/864293?dopt=AbstractPlus

57. Neu HC. Amoxicillin. Ann Intern Med. 1979; 90:356-60. http://www.ncbi.nlm.nih.gov/pubmed/34342?dopt=AbstractPlus

59. Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. J Clin Pharmacol. 1981; 21:456-8. http://www.ncbi.nlm.nih.gov/pubmed/6458626?dopt=AbstractPlus

60. Mulroy R. Amoxycillin rash in infectious mononucleosis. Br Med J. 1973; 1:554. http://www.ncbi.nlm.nih.gov/pubmed/4266345?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1588712&blobtype=pdf

61. Jick H, Slone D, Shapiro S et al. Excess of ampicillin rashes associated with allopurinol or hyperuricemia. N Engl J Med. 1972; 286:505-7. http://www.ncbi.nlm.nih.gov/pubmed/4258181?dopt=AbstractPlus

62. Chambers HF. Penicillins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000: 261-74.

63. Nolan CM, White PC. Treatment of typhoid carriers with amoxicillin: correlates of successful therapy. JAMA. 1978; 239:2352-4. http://www.ncbi.nlm.nih.gov/pubmed/642172?dopt=AbstractPlus

64. Howard JB, Aquirre X, Palombo G. Amoxicillin versus ampicillin for treatment of typhoid fever in children. Curr Ther Res Clin Exp. 1980; 28:491-7.

65. Munnich D, Bekesi S. Curing of typhoid carriers by cholecystectomy combined with amoxycillin plus probenecid treatment. Chemotherapy. 1979; 25:362-6. http://www.ncbi.nlm.nih.gov/pubmed/520079?dopt=AbstractPlus

66. Abengowe CU. Comparative clinical trial of amoxycillin and chloramphenicol in the treatment of typhoid in adults. J Int Med Res. 1979; 7:247-51. http://www.ncbi.nlm.nih.gov/pubmed/378735?dopt=AbstractPlus

67. Munnich D, Bekesi S, Lakatos M et al. Treatment of typhoid carriers with amoxycillin and in combination with probenecid. Chemotherapy. 1974; 20:29-38. http://www.ncbi.nlm.nih.gov/pubmed/4846500?dopt=AbstractPlus

68. Scragg JN. Further experience with amoxycillin in typhoid fever in children. Br Med J. 1976; 2:1031-3. http://www.ncbi.nlm.nih.gov/pubmed/990748?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1689146&blobtype=pdf

69. Shanson DC, Cannon P, Wilks M. Amoxycillin compared with penicillin V for prophylaxis of dental bacteraemia. J Antimicrob Chemother. 1978; 4:431-6. http://www.ncbi.nlm.nih.gov/pubmed/99423?dopt=AbstractPlus

72. Shanson DC, Ashford RF, Singh J. High-dose oral amoxycillin for preventing endocarditis. Br Med J. 1980; 280:446. http://www.ncbi.nlm.nih.gov/pubmed/7370526?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1600433&blobtype=pdf

73. Mackay AD. Amoxycillin versus ampicillin in treatment of exacerbations of chronic bronchitis. Br J Dis Chest. 1980; 74:379-83. http://www.ncbi.nlm.nih.gov/pubmed/7011353?dopt=AbstractPlus

74. Committee on Infectious Diseases. Policy statement: recommendations for prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000; 106:362-6. http://www.ncbi.nlm.nih.gov/pubmed/10920169?dopt=AbstractPlus

75. Ronald AR, Jagdis FA, Harding GK et al. Amoxicillin therapy of acute urinary infections in adults. Antimicrob Agents Chemother. 1977; 11:780-4. http://www.ncbi.nlm.nih.gov/pubmed/327919?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352074&blobtype=pdf

76. Savard-Fenton M, Fenton BW, Reller LB et al. Single-dose amoxicillin therapy with follow-up urine culture: effective initial management for acute uncomplicated urinary tract infections. Am J Med. 1982; 73:808-13. http://www.ncbi.nlm.nih.gov/pubmed/6924538?dopt=AbstractPlus

78. Souney P, Polk BF. Single-dose antimicrobial therapy for urinary tract infections in women. Rev Infect Dis. 1982; 4:29-34. http://www.ncbi.nlm.nih.gov/pubmed/6918057?dopt=AbstractPlus

79. Mayo JB, McCarthy LR. Antimicrobial susceptibility of Haemophilus parainfluenzae. Antimicrob Agents Chemother. 1977; 11:844-7. http://www.ncbi.nlm.nih.gov/pubmed/587028?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=352084&blobtype=pdf

81. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 2001; 43:69-78. http://www.ncbi.nlm.nih.gov/pubmed/11518876?dopt=AbstractPlus

82. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med. 1977; 296:663-70. http://www.ncbi.nlm.nih.gov/pubmed/402574?dopt=AbstractPlus

83. Bennett WM, Aronoff GR, Morrison G et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983; 3:155-93. http://www.ncbi.nlm.nih.gov/pubmed/6356890?dopt=AbstractPlus

84. SmithKline Beecham. Augmentin (amoxicillin and clavulanate potassium) chewable tablets and powder for oral suspension prescribing information. Research Triangle Park, NC; 2003 Jan.

85. Yogev R, Melick C, Kabat WJ. In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b. Antimicrob Agents Chemother. 1981; 19:993-6. http://www.ncbi.nlm.nih.gov/pubmed/6973952?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=181597&blobtype=pdf

86. Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: an antibiotic combination: mechanisms of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy. 1984; 4:122-36. http://www.ncbi.nlm.nih.gov/pubmed/6739312?dopt=AbstractPlus

87. Fuglesang JE, Bergan T. Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes. Infection. 1983; 11:329-35. http://www.ncbi.nlm.nih.gov/pubmed/6365790?dopt=AbstractPlus

88. Markowitz LE, Steere AC, Benach JL et al. Lyme disease during pregnancy. JAMA. 1986; 255:3394-6. http://www.ncbi.nlm.nih.gov/pubmed/2423719?dopt=AbstractPlus

89. American Medical Association Council on Scientific Affairs. Aspartame: review of safety issues. JAMA. 1985; 254:400-2. http://www.ncbi.nlm.nih.gov/pubmed/2861297?dopt=AbstractPlus

90. Gossel TA. A review of aspartame: characteristics, safety and uses. US Pharm. 1984; 9:26, 28-30.

91. Food and Drug Administration. Aspartame as an inactive ingredient in human drug products; labeling requirements. Proposed rule. (21 CFR Part 201) Fed Regist. 1983; 48:54993-5. (IDIS 178728)

92. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption: aspartame. Final rule. (21 CFR Part 172) Fed Regist. 1983; 48:31376-82. (IDIS 172957)

93. Anon. Aspartame and other sweeteners. Med Lett Drugs Ther. 1982; 24:1-2. http://www.ncbi.nlm.nih.gov/pubmed/7054648?dopt=AbstractPlus

97. Petersen EA. Prevention of bacterial endocarditis. Arch Intern Med. 1990; 150:2447-8. http://www.ncbi.nlm.nih.gov/pubmed/2244761?dopt=AbstractPlus

99. American Heart Association, American Dental Association Council on Dental Therapeutics. Preventing bacterial endocarditis: a statement for the dental professional. J Am Dent Assoc. 1991; 122:87-92.

100. Kaye D, Abrutyn E. Prevention of bacterial endocarditis: 1991. Ann Intern Med. 1991; 114:803-4. http://www.ncbi.nlm.nih.gov/pubmed/2012361?dopt=AbstractPlus

101. Cawson RA. Antibiotic prophylaxis for dental treatment: for hearts but not for prosthetic joints. BMJ. 1992; 304:933-4. http://www.ncbi.nlm.nih.gov/pubmed/1581713?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1882313&blobtype=pdf

102. Zenilman JM. Typhoid fever. JAMA. 1997; 278:847-50. http://www.ncbi.nlm.nih.gov/pubmed/9293994?dopt=AbstractPlus

103. Klein JO. Protecting the therapeutic advantage of antimicrobial agents used for otitis media. Pediatr Infect Dis J. 1998; 17:571-5. http://www.ncbi.nlm.nih.gov/pubmed/9655563?dopt=AbstractPlus

104. Paradise JL. Managing otitis media: a time for change. Pediatrics. 1995; 96:712-5. http://www.ncbi.nlm.nih.gov/pubmed/7567336?dopt=AbstractPlus

106. Hirschmann JV. Methods for decreasing antibiotic use in otitis media. Lancet. 1998; 352:672. http://www.ncbi.nlm.nih.gov/pubmed/9728980?dopt=AbstractPlus

107. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992; 87:1716-27. http://www.ncbi.nlm.nih.gov/pubmed/1449132?dopt=AbstractPlus

108. Esposito S, Marchisio P, Bosis S et al. Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children. Int J Antimicrob Agents. 2002; 20:28-33. http://www.ncbi.nlm.nih.gov/pubmed/12127708?dopt=AbstractPlus

109. Aquilar A, Tinoco JC, Macias M et al. Clincial and bacteriologic efficacy of amoxycillin b.d. (45 mg/kg/day) versus amoxycillin t.d.s (40 mg/kg/day) in children with group A beta-hemolytic streptococcal tonsillopharyngitis. J Chemother. 2000; 12:396-405. http://www.ncbi.nlm.nih.gov/pubmed/11128559?dopt=AbstractPlus

110. Feder HM, Gerber MA, Randolph MF et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics. 1999; 103:47-51. http://www.ncbi.nlm.nih.gov/pubmed/9917438?dopt=AbstractPlus

111. Berman S, Roark R, Luckey D. Theoretical cost effectiveness of management options for children with persisting middle ear effusions. Pediatrics. 1994; 93:353-63. http://www.ncbi.nlm.nih.gov/pubmed/8115191?dopt=AbstractPlus

112. Bayerdörffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. http://www.ncbi.nlm.nih.gov/pubmed/8341987?dopt=AbstractPlus

113. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.

115. Hsu GS, Levine SC, Giebink GS. Management of otitis media using agency for health care policy and research guidelines. Otolaryngol Head Neck Surg. 1998; 118:437-43. http://www.ncbi.nlm.nih.gov/pubmed/9560092?dopt=AbstractPlus

116. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. http://www.ncbi.nlm.nih.gov/pubmed/8341990?dopt=AbstractPlus

117. Adamek RJ, Wegener M, Opferkuch W et al. Successful Helicobacter pylori eradication: a systemic effect of antibiotics? Am J Gastroenterol. 1993; 88:792-3. Letter.

118. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut. 1993; 34:466-9. http://www.ncbi.nlm.nih.gov/pubmed/8491391?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1374304&blobtype=pdf

119. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust. 1990; 153:145-9. http://www.ncbi.nlm.nih.gov/pubmed/1974027?dopt=AbstractPlus

120. Centers for Disease Control and Prevention. Diagnosis and management of foodborne illnesses: a primer for physicians. MMWR Morb Mortal Wkly Rep. 2001; 50(No. RR-2):1-69. http://www.ncbi.nlm.nih.gov/pubmed/11215787?dopt=AbstractPlus

121. Guerrant RL, Gilder TV, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001; 32:331-50. http://www.ncbi.nlm.nih.gov/pubmed/11170940?dopt=AbstractPlus

122. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992; 116:705-8. http://www.ncbi.nlm.nih.gov/pubmed/1558340?dopt=AbstractPlus

123. Axon AT. Helicobacter pylori therapy: effect on peptic ulcer disease. J Gastroenterol Hepatol. 1991; 6:131-7. http://www.ncbi.nlm.nih.gov/pubmed/1912418?dopt=AbstractPlus

124. Benson JM, Nahata MC. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination. DICP. 1988; 22:534-41.

125. Campoli-Richards DM, Brogden RN. Sulbactam/ampicillin: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs. 1987; 33:577-609. http://www.ncbi.nlm.nih.gov/pubmed/3038500?dopt=AbstractPlus

126. Chamberland S, L’Ecuyer J, Lessard C et al. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. Clin Infect Dis. 1992; 15:615-28. http://www.ncbi.nlm.nih.gov/pubmed/1420674?dopt=AbstractPlus

127. Wexler HM, Molitoris E, Finegold SM. Effect of β-lactamase inhibitors on the activities of various β-lactam agents against anaerobic bacteria. Antimicrob Agents Chemother. 1991; 1219-24.

128. Driessen OM, Sorgedrager N, Michel MF et al. Variability and predictability of the plasma concentration of ampicillin and kanamycin in new-born infants. Eur J Clin Pharmacol. 1979; 15:133-7. http://www.ncbi.nlm.nih.gov/pubmed/436921?dopt=AbstractPlus

129. Spera RV, Farber BF. Multiply-resistant Enterococcus faecium: the nosocomial pathogen of the 1990s. JAMA. 1993; 268:2563-4.

130. Klare I, Rodloff AC, Wagner J et al. Overproduction of a penicillin-binding protein is not the only mechanism of penicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother. 1992; 36:783-7. http://www.ncbi.nlm.nih.gov/pubmed/1503440?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=189409&blobtype=pdf

131. Handwerger S, Perlman DC, Altarae D et al. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of Enterococci. Clin Infect Dis. 1992; 14: 655-61.

132. Rhinehart E, Smith NE, Wennersten C et al. Rapid dissemination of β-lactamase-producing, aminoglycoside-resistant, Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990; 323:1814-8. http://www.ncbi.nlm.nih.gov/pubmed/2123301?dopt=AbstractPlus

133. Murray BE. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis. 1991; 163:1185-94.

134. Coudron PE, Markowitz SM, Wong ES. Isolation of a β-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium. Antimicrob Agents Chemother. 1992; 36:1125-6. http://www.ncbi.nlm.nih.gov/pubmed/1510404?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=188847&blobtype=pdf

135. Markowitz SM, Wells VD, Williams DS et al. Antimicrobial susceptibility and molecular epidemiology of β-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis. Antimicrob Agents Chemother. 1991; 35:1075-80. http://www.ncbi.nlm.nih.gov/pubmed/1929246?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=284289&blobtype=pdf

136. Chirurgi V, Oster SE, Goldberg AA et al. Nosocomial acquisition of β-lactamase-negative, ampicillin-resistant Enterococcus. Arch Intern Med. 1992; 152:1457-61. http://www.ncbi.nlm.nih.gov/pubmed/1627025?dopt=AbstractPlus

137. Rosioru C, Glassman MS, Halata MS et al. Esophagitis and Helicobacter pylori in children: incidence and therapeutic implications. Am J Gastroenterol. 1993; 88:510-3. http://www.ncbi.nlm.nih.gov/pubmed/8470630?dopt=AbstractPlus

138. Oderda G, Forni M, Dell’Olio D et al. Cure of peptic ulcer associated with eradication of Helicobacter pylori. Lancet. 1990; 335:1599.

140. Anon. Drugs for treatment of acute otitis media in children. Med Lett Drug Ther. 1994; 36:19-21.

141. Pichichero ME. Assessing the treatment of alternatives for acute otitis media. Pediatr Infect Dis J. 1994; 13:S27-34. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2993315&blobtype=pdf

142. Bigby M, Jick S, Jick H et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986; 256:3358-63. http://www.ncbi.nlm.nih.gov/pubmed/2946876?dopt=AbstractPlus

143. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89:S116-28.

144. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. http://www.ncbi.nlm.nih.gov/pubmed/8406147?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1375447&blobtype=pdf

145. Labenz J, Gyenes E, Rühl GH et al. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993; 88:491-5. http://www.ncbi.nlm.nih.gov/pubmed/8470626?dopt=AbstractPlus

146. Bell GD, Powell KU, Burridge SM et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med. 1993; 86:743-50. http://www.ncbi.nlm.nih.gov/pubmed/8265776?dopt=AbstractPlus

147. Labenz J, Rühl GH, Bertrams J et al. Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci. 1994; 39:1483-7. http://www.ncbi.nlm.nih.gov/pubmed/8026260?dopt=AbstractPlus

148. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994; 89:1785-8. http://www.ncbi.nlm.nih.gov/pubmed/7942667?dopt=AbstractPlus

149. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994; 89:1793-6. http://www.ncbi.nlm.nih.gov/pubmed/7942669?dopt=AbstractPlus

150. Savarino V, Mela GS, Zentilin P et al. Acid inhibition and amoxicillin activity against Helicobacter pylori. Am J Gastroenterol. 1993; 88:1975-6. http://www.ncbi.nlm.nih.gov/pubmed/8237959?dopt=AbstractPlus

151. Anon. Drugs for treatment of peptic ulcer. Med Lett Drugs Ther. 1994; 36:65-7. http://www.ncbi.nlm.nih.gov/pubmed/7912812?dopt=AbstractPlus

152. Freston JW. Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol. 1994; 29(Suppl 201):49-54.

153. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol. 1994; 29(Suppl 201):16-23.

154. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. http://www.ncbi.nlm.nih.gov/pubmed/8172146?dopt=AbstractPlus

155. Aujard Y, Boucot I, Brahimi N et al. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J. 1995; 14:295-300. http://www.ncbi.nlm.nih.gov/pubmed/7603811?dopt=AbstractPlus

156. Klass PE, Klein JO. Therapy of bacterial sepsis, meningitis and otitis media in infants and children: 1992 poll of directors of programs in pediatric infectious diseases. Pediatr Infect Dis J. 1992; 11:702-5. http://www.ncbi.nlm.nih.gov/pubmed/1448307?dopt=AbstractPlus

157. Alary M, Joly JR, Moutquin JM et al. Randomised comparison of amoxycillin and erythromycin in treatment of genital chlamydial infection in pregnancy. Lancet. 1994; 344:1461-5. http://www.ncbi.nlm.nih.gov/pubmed/7968119?dopt=AbstractPlus

158. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91. http://www.ncbi.nlm.nih.gov/pubmed/7666920?dopt=AbstractPlus

159. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Saf. 1996; 15:30-52. http://www.ncbi.nlm.nih.gov/pubmed/8862962?dopt=AbstractPlus

160. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs. 1995; 6:984-90.

161. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. http://www.ncbi.nlm.nih.gov/pubmed/8594244?dopt=AbstractPlus

162. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1:6-19. http://www.ncbi.nlm.nih.gov/pubmed/9398908?dopt=AbstractPlus

163. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1:138-44. http://www.ncbi.nlm.nih.gov/pubmed/9398894?dopt=AbstractPlus

164. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. http://www.ncbi.nlm.nih.gov/pubmed/8741237?dopt=AbstractPlus

165. Bourke B, Jones N, Sherman P. Helicobacter pylori infection and peptic ulcer disease in children. Pediatr Infect Dis J. 1996; 15:1-13. http://www.ncbi.nlm.nih.gov/pubmed/8684868?dopt=AbstractPlus

166. Rowland M, Drumm B. Helicobacter pylori infection and peptic ulcer disease in children. Curr Opin Pediatr. 1995; 7:553-9. http://www.ncbi.nlm.nih.gov/pubmed/8541956?dopt=AbstractPlus

167. Bujanover Y, Reif S, Yahav J. Helicobacter pylori and peptic disease in the pediatric patient. Pediatr Clin North Am. 1996; 43:213-34. http://www.ncbi.nlm.nih.gov/pubmed/8596681?dopt=AbstractPlus

168. TAP Pharmaceuticals. Prevacid (lansoprazole) prescribing information. Lake Forest, IL: 2003 Nov.

169. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997; 54:473-500. http://www.ncbi.nlm.nih.gov/pubmed/9279507?dopt=AbstractPlus

171. Lederle. Methotrexate sodium tablets, methotrexate sodium for injection, methotrexate LPF sodium injection, and methotrexate sodium injection prescribing information. Pearl River, NY; 2001 Aug 28.

172. TAP Pharmaceuticals. PrevPac (lansoprazole 30-mg capsules, amoxicillin 500-mg capsules, and clarithromycin 500-mg tablets) prescribing information. Lake Forest, IL; 2002 Oct.

173. AstraZeneca. Prilosec (omeprazole) delayed release capsules prescribing information. Wilmington,DE; 2002 Jul.

174. Abbott Laboratories. Biaxin (clarithromycin) Filmtab tablets, XL Filmtab extended-release tablets, and granules for oral suspension) prescribing information. North Chicago, IL; 2003 May.

175. Salcedo JA, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med. 1998; 158:842-51. http://www.ncbi.nlm.nih.gov/pubmed/9570169?dopt=AbstractPlus

176. Klein JO. Selection of oral antimicrobial agents for otitis media and pharyngitis. Infect Dis Clin Pract. 1995; 4(Suppl 2):S88-94.

177. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J. 1997; 16:680-95. http://www.ncbi.nlm.nih.gov/pubmed/9239773?dopt=AbstractPlus

179. Nocton JJ, Steere AC. Lyme disease. Adv Intern Med. 1995; 40:69-117.

181. Nadelman RB, Wormser GP. Erythema migrans and early Lyme disease. Am J Med. 1995; 98(4A):15-23S.

182. Steere AC. Musculoskeletal manifestations of Lyme disease. Am J Med. 1995; 98(4A):44S-48S. http://www.ncbi.nlm.nih.gov/pubmed/7726191?dopt=AbstractPlus

183. Rees DHE, Axford JS. Lyme arthritis. Ann Rheum Dis. 1994; 53:553-6. http://www.ncbi.nlm.nih.gov/pubmed/7979590?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1005402&blobtype=pdf

184. Spach DH, Liles WC, Campbell GL et al. Tick-borne diseases in the United States. N Engl J Med. 1993; 329:936-47.

185. Sigal LH. Early disseminated Lyme disease: cardiac manifestations. Am J Med. 1995; 98(4A):25S-28S. http://www.ncbi.nlm.nih.gov/pubmed/7726189?dopt=AbstractPlus

186. Sigal LH. Management of Lyme disease refractory to antibiotic therapy. Rheum Dis Clin North Am. 1995; 21:217-30.

187. Shapiro ED. Lyme disease in children. Am J Med. 1995; 98(4A):69S-73S. http://www.ncbi.nlm.nih.gov/pubmed/7726195?dopt=AbstractPlus

188. Nadelman RB, Wormser GP. Lyme borreliosis. Lancet. 1998; 352:557-65. http://www.ncbi.nlm.nih.gov/pubmed/9716075?dopt=AbstractPlus

190. Committee on Infectious Diseases, American Academy of Pediatrics. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:80-1,196-9,407-11,541-7,573-84,773.

191. Rahn DW, Felz MW. Lyme disease update. Current approach to early, disseminated, and late disease. Postgrad Med. 1998; 103:51-4, 57-9, 63-4. http://www.ncbi.nlm.nih.gov/pubmed/9590986?dopt=AbstractPlus

192. McCracken GH. Treatment of acute otitis media in an era of increasing microbial resistance. Pediatr Infect Dis J. 1998; 17:576-9. http://www.ncbi.nlm.nih.gov/pubmed/9655564?dopt=AbstractPlus

193. Klein JO. Otitis Media. Clin Infect Dis J. 1994; 19:823-33.

194. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998; 26:1027-36. http://www.ncbi.nlm.nih.gov/pubmed/9597221?dopt=AbstractPlus

199. Bauchner H, Adams W, Barnett E et al. Therapy for acute otitis media: preference of parents for oral or parenteral antibiotics. Arch Pediatr Adolesc Med. 1996; 150:396-9. http://www.ncbi.nlm.nih.gov/pubmed/8634735?dopt=AbstractPlus

200. Dowell SF, Butler JC, Giebink GS et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance—a report from the drug-resistant Streptococcal pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999; 18:1-9. http://www.ncbi.nlm.nih.gov/pubmed/9951971?dopt=AbstractPlus

201. Klein JO. Current recommendations on the therapy of otitis media. Pediatr Infect Dis J. 1998; 17:1058-9. http://www.ncbi.nlm.nih.gov/pubmed/9849999?dopt=AbstractPlus

202. Klein JO. Clinical implications of antibiotic resistance for management of acute otitis media. Pediatr Infect Dis J. 1998; 17:1084-9. http://www.ncbi.nlm.nih.gov/pubmed/9850003?dopt=AbstractPlus

203. Blumer JL. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. Pediatr Infect Dis J. 1998; 17:1070-5. http://www.ncbi.nlm.nih.gov/pubmed/9850001?dopt=AbstractPlus

204. Jacobs MR. Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update. Pediatr Infect Dis J. 1998; 17:947-52. http://www.ncbi.nlm.nih.gov/pubmed/9802651?dopt=AbstractPlus

205. Poole MD. Implications of drug-resistant Streptococcus pneumoniae for otitis media. Pediatr Infect Dis J. 1998; 17:953-6. http://www.ncbi.nlm.nih.gov/pubmed/9802652?dopt=AbstractPlus

206. Dowell SF, Marcy SM, Phillips WR et al. Otitis media—principles of judicious use of antimicrobial agents. Pediatrics. 1998; 101:165-71.

207. Williams RL, Chalmers TC, Stange KC et al. Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion: a meta-analytic attempt to resolve the brouhaha. JAMA. 1993; 270:1344-51. http://www.ncbi.nlm.nih.gov/pubmed/8141875?dopt=AbstractPlus

208. Stool SE, Berg AO, Berman S et al for the Otitis Media Guideline Panel. Otitis media with effusion in young children. Clinical Practice Guideline. Number 12. AHCPR Publication No. 94-0622. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Resources. July 1994.

209. Berman S. Otitis media in children. N Engl J Med. 1995; 332:1560-5. http://www.ncbi.nlm.nih.gov/pubmed/7739711?dopt=AbstractPlus

210. Bluestone CD. Current therapy for otitis media and criteria for evaluation of new antimicrobial agents. Clin Infect Dis. 1992; 14(Suppl 2):S197-203. http://www.ncbi.nlm.nih.gov/pubmed/1617038?dopt=AbstractPlus

211. White LL, Holimon TD, Tepedino JT et al. Antimicrobials prescribed for otitis media in a pediatric Medicaid population. Am J Health-Syst Pharm. 1996; 53:2963-9. http://www.ncbi.nlm.nih.gov/pubmed/8974159?dopt=AbstractPlus

212. Block SL, Harrison CJ, Hedrick JA et al. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: risk factors, susceptibility patterns and antimicrobial management. Pediatr Infect Dis J. 1995; 14:751-9. http://www.ncbi.nlm.nih.gov/pubmed/8559623?dopt=AbstractPlus

213. Oh PI, Maerov P, Pritchard D et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther. 1996; 18:160-82. http://www.ncbi.nlm.nih.gov/pubmed/8851461?dopt=AbstractPlus

214. Perry BP, Zieno SA, Yonkers AJ. Outcome-oriented managed care comparing efficacies of cefaclor and amoxicillin in acute and recurrent acute otitis media. Ear Nose Throat J. 1995; 74:840-4. http://www.ncbi.nlm.nih.gov/pubmed/8556984?dopt=AbstractPlus

215. Cohen R, Navel M, Grunberg J et al. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J. 1999; 18:403-9. http://www.ncbi.nlm.nih.gov/pubmed/10353511?dopt=AbstractPlus

216. Ball P. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am J Med. 1999; 107(Suppl 1A):77S-85S. http://www.ncbi.nlm.nih.gov/pubmed/10451013?dopt=AbstractPlus

217. Adderson EE. Preventing otitis media: medical approaches. Pediatr Ann. 1998; 27:101-7. http://www.ncbi.nlm.nih.gov/pubmed/9523298?dopt=AbstractPlus

218. Hoppe HL, Johnson CE. Otitis media: focus on antimicrobial resistance and new treatment options. Am J Health-Syst Pharm. 1998; 55:1881-97. http://www.ncbi.nlm.nih.gov/pubmed/9784768?dopt=AbstractPlus

219. Bluestone CD. Ear and mastoid infections. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia, PA: WB Saunders; 1998:530-9.

220. Roark R, Berman S. Continuous twice daily or once daily amoxicillin prophylaxis compared with placebo for children with recurrent acute otitis media. Pediatr Infect Dis J. 1997; 16:376-81. http://www.ncbi.nlm.nih.gov/pubmed/9109139?dopt=AbstractPlus

221. Thomsen J, Sederberg-Olsen J, Balle V et al. Antibiotic treatment of children with secretory otitis media: amoxicillin-clavulanate is superior to penicillin V in a double-blind randomized study. Arch Otolaryngol Head Neck Sur. 1997; 123:695-9.

222. Mandel EM, Casselbrant ML, Rockette HE et al. Efficacy of antimicrobial prophylaxis for recurrent middle ear effusion. Pediatr Infect Dis J. 1996; 15:1074-82. http://www.ncbi.nlm.nih.gov/pubmed/8970215?dopt=AbstractPlus

223. Marchisio P, Principi N, Sala E et al. Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. Antimicrob Agents Chemother. 1996; 40:2732-6. http://www.ncbi.nlm.nih.gov/pubmed/9124831?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=163612&blobtype=pdf

224. Casselbrant ML, Kaleida PH, Rockette HE et al. Efficacy of antimicrobial prophylaxis and of tympanostomy tube insertion for prevention of recurrent acute otitis media: results of a randomized clinical trial. Pediatr Infect Dis J. 1992; 11:278-86. http://www.ncbi.nlm.nih.gov/pubmed/1565551?dopt=AbstractPlus

225. Berman S, Nuss R, Roark R et al. Effectiveness of continuous vs. intermittent amoxicillin to prevent episodes of otitis media. Pediatr Infect Dis J. 1992; 11:63-7. http://www.ncbi.nlm.nih.gov/pubmed/1741200?dopt=AbstractPlus

226. Heikkinen T, Ruuskanen O, Ziegler T et al. Short-term use of amoxicillin-clavulanate during upper respiratory tract infection for prevention of acute otitis media. J Pediatr. 1995; 126:313-6. http://www.ncbi.nlm.nih.gov/pubmed/7844685?dopt=AbstractPlus

227. Mandel EM, Rockette HE, Paradise JL et al. Comparative efficacy of erythromycin-sulfisoxazole, cefaclor, amoxicillin or placebo for otitis media with effusion in children. Pediatr Infect Dis J. 1991; 10:899-906. http://www.ncbi.nlm.nih.gov/pubmed/1766705?dopt=AbstractPlus

228. Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000; 49(No. RR-15):1-22. http://www.ncbi.nlm.nih.gov/pubmed/10993565?dopt=AbstractPlus http://www.cdc.gov/mmwr/PDF/rr/rr4915.pdf

229. Dixon TC, Meselson M, Guillemin J et al. Anthrax. N Engl J Med. 1999; 341:815-26. http://www.ncbi.nlm.nih.gov/pubmed/10477781?dopt=AbstractPlus

230. Turnball PCB. Guidelines for surveillance and control of anthrax in human and animals. 3rd ed. Geneva, Switzerland: World Health Organization, Department of Communicable Diseases Surveillance and Response. Publication No. WHO/EMC/ZSI./98.6. 1998. From WHO website http://www.who.int

231. Inglesby TV, O’Toole T, Henderson DA et al for the Working Group on Civilian Biodefense. Anthrax as a biological weapon 2002: updated recommendations for management. JAMA. 2002; 287:2236-52. http://www.ncbi.nlm.nih.gov/pubmed/11980524?dopt=AbstractPlus

232. Steere AC. Lyme disease. N Engl J Med. 2001; 345:115-25. http://www.ncbi.nlm.nih.gov/pubmed/11450660?dopt=AbstractPlus

233. Centers for Disease Control and Prevention. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep. 2001; 50:889-93. http://www.ncbi.nlm.nih.gov/pubmed/11686472?dopt=AbstractPlus

234. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001; 50:909-19. http://www.ncbi.nlm.nih.gov/pubmed/11699843?dopt=AbstractPlus

235. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biologic casualties handbook. 4th ed. USAMRIID: Fort Detrick, MD; 2001 Feb.

236. Centers for Disease Control and Prevention. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. 2001; 50:960.

237. Swartz MN. Recognition and management of anthrax—an update. N Engl J Med. 2001; 345:1621-6. http://www.ncbi.nlm.nih.gov/pubmed/11704686?dopt=AbstractPlus

238. Wormser GP, Nadelman RB, Dattwyler R et al. Infectious Diseases Society of America. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis. 2000; 31(Suppl 1):S1-14. http://www.ncbi.nlm.nih.gov/pubmed/10982743?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2573401&blobtype=pdf

239. Centers for Disease Control and Prevention. Notice to readers: update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep. 2001; 50:1014-6. http://www.ncbi.nlm.nih.gov/pubmed/11724160?dopt=AbstractPlus

243. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000; 49(No. RR-9):1-55. http://www.ncbi.nlm.nih.gov/pubmed/10993565?dopt=AbstractPlus http://www.cdc.gov/mmwr/PDF/rr/rr4909.pdf

245. American Academy of Pediatrics, American Academy of Family Physicians, American Academy of Otolaryngology-Head and Neck Surgery et al. Otitis media with effusion. Pediatrics. 2004; 113:1412-29. http://www.ncbi.nlm.nih.gov/pubmed/15121966?dopt=AbstractPlus

292. American Academy of Pediatrics. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.

302. McDonald LC, Gerding DN, Johnson S et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66:987-994. http://www.ncbi.nlm.nih.gov/pubmed/29562266?dopt=AbstractPlus

329. Lantos PM, Rumbaugh J, Bockenstedt LK et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021; 72:e1-e48. http://www.ncbi.nlm.nih.gov/pubmed/33417672?dopt=AbstractPlus

331. . Antibacterial drugs for Lyme disease. Med Lett Drugs Ther. 2021; 63:73-75. http://www.ncbi.nlm.nih.gov/pubmed/33976091?dopt=AbstractPlus

344. Workowski KA, Bachmann LH, Chan PA et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021; 70:1-187. http://www.ncbi.nlm.nih.gov/pubmed/34292926?dopt=AbstractPlus

375. Gerber MA, Baltimore RS, Eaton CB et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009; 119:1541-51. http://www.ncbi.nlm.nih.gov/pubmed/19246689?dopt=AbstractPlus

451. Wilson W, Taubert KA, Gewitz M et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116:1736-54. http://www.ncbi.nlm.nih.gov/pubmed/17446442?dopt=AbstractPlus

580. Shulman ST, Bisno AL, Clegg HW et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012; 55:1279-82. Updates may be available at IDSA website at www.idsociety.org. http://www.ncbi.nlm.nih.gov/pubmed/23091044?dopt=AbstractPlus

671. Bradley JS, Peacock G, Krug SE et al. Pediatric anthrax clinical management. Pediatrics. 2014; 133:e1411-36. http://www.ncbi.nlm.nih.gov/pubmed/24777226?dopt=AbstractPlus

672. Meaney-Delman D, Zotti ME, Creanga AA et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014; 20:e1-6. http://www.ncbi.nlm.nih.gov/pubmed/24457117?dopt=AbstractPlus

673. Hendricks KA, Wright ME, Shadomy SV et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014; 20 http://www.ncbi.nlm.nih.gov/pubmed/24447897?dopt=AbstractPlus

683. Lieberthal AS, Carroll AE, Chonmaitree T et al. The diagnosis and management of acute otitis media. Pediatrics. 2013; 131:e964-99. http://www.ncbi.nlm.nih.gov/pubmed/23439909?dopt=AbstractPlus

Frequently asked questions

View more FAQ

Medical Disclaimer